A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman, S., Buongervino, S.N., Lane, M.V., Zhelev, D.V., Zhu, Z., Cui, H., Martinez, B., Martinez, D., Wang, Y., Upton, K., Patel, K., Rathi, K.S., Navia, C.T., Harmon, D.B., Li, Y., Pawel, B., Dimitrov, D.S., Maris, J.M., Julien, J.P., Bosse, K.R.(2021) Cell Rep Med 2: 100344-100344
- PubMed: 34337560 
- DOI: 10.1016/j.xcrm.2021.100344
- Primary Citation of Related Structures:  
6WJL - PubMed Abstract: 
Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2's immunotherapeutic attributes by finding that it is also a highly expressed, MYCN-driven oncoprotein on small-cell lung cancers (SCLCs), with significantly enriched expression in both the SCLC and neuroblastoma stem cell compartment ...